Artificial intelligence (AI)-driven investigations into COVID treatments by scientists at the U.S. Department of Energy's Pacific Northwest National Laboratory (PNNL) are yielding insights for application to future pandemic responses.
PNNL's Jeremy Zucker and colleagues used a counterfactual AI framework to simulate biochemical data collected from hypothetical patients with severe COVID-19 infections; each fictitious patient had different viral loads, received a different dose of a drug, and either recovered or died.
The analysis delivered more precise information about the drug's potential benefit to individuals, compared with algorithms that just predicted average patient post-treatment outcomes.
Researchers at PNNL and the University of Washington also combined high-throughput biochemical measurements and AI-based screening to extract one molecule with promising antiviral activity against SARS-CoV-2 out of 13,000.
From Pacific Northwest National Laboratory
View Full Article
Abstracts Copyright © 2021 SmithBucklin, Washington, DC, USA